Evidence map›Paper›PMID 25196710›Full record

ArticleClinical and translational science2015

Understanding the supports of and challenges to community engagement in the CTSAs.

Jessica Holzer, Nancy Kass

Abstract read
In one paragraph

Article in Clinical and translational science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The development, validity, and reliability of the Researcher Investment Tool.Journal of clinical and translational science · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica HolzerDepartment of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA.
Nancy Kass

Funding

Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Yale Training Program in Health Services ResearchT32HS017589 · AHRQ · YALE UNIVERSITY · PI SCHLESINGER, MARK J · 2008 to 2024
$5.6M
AHRQ HHS T32 HS017589NCATS NIH HHS UL1 TR001079NCRR NIH HHS 5 UL1 RR025005 05NCRR NIH HHS UL1 RR025005NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

backgroundThe Clinical and Translational Science Award (CTSA) program has raised the profile and the available funding for engagement in biomedical research. Such increased funding and attention may address known barriers to engagement. However, little work has been done to describe experiences across multiple CTSAs, especially how the CTSA structure supports or challenges engagement.

objectiveWe sought to understand the supports and challenges experienced by multiple CTSAs as they pursued community engagement. This knowledge may help guide future efforts to support and enhance community engagement in biomedical research.

methodsWe conducted semi-structured, in-depth interviews with CTSA community engagement core leaders and staff from the 2006 cohort of CTSAs (n = 12).

resultsA total of 17 interviews with respondents from nine institutions identified three support themes, including: funding, existing relationships with communities, and leadership and a partnership approach at the institution. Six challenge themes arose: need for capacity development, lack of positive relationships with communities, lack of leadership, funding constraints, time and staff constraints, and unsustainable models.

conclusionThe CTSAs have brought much-needed attention to community engagement in research, but more can be done to adequately support engagement. Challenges remain that need to be addressed to achieve the potential benefits of engagement.

Indexed as

Biomedical ResearchClinical Trials as TopicCohort StudiesCommunity-Institutional RelationsLeadershipNational Institutes of Health (U.S.)Program DevelopmentProgram EvaluationResidence CharacteristicsTranslational Research, BiomedicalUnited Stateschallengesclinical trialscommunity engagementsupporting factorstranslational research

Identifiers

PMID25196710
PMCPMC4362794

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.